2-(Benzoyl)piperidines (analogues of 1a),
structural
hybrids of the clinically employed ADHD medication methylphenidate
(2) and the abused synthetic cathinone pentedrone (3), have been previously reported to act as novel and selective
reuptake inhibitors of the human dopamine transporter (hDAT). One
of the more potent benzoylpiperidines, as is the case with methylphenidate
analogues, is its 3,4-dichloroaryl counterpart. Here, we demonstrate
using homology models that these compounds (i.e., benzoylpiperidines
and methylphenidate analogues) likely bind in a comparable manner
at hDAT. In addition, it is shown here that the 3,4-dichlorobenzoylpiperidine
analogue of 1a is more potent than its 3,4-dimethyl counterpart,
suggesting that the electronic character of the substituents might
play a role in the potency of these hybrids. Furthermore, the 3,4-benz-fused
(i.e., naphthyl) benzoylpiperidine analogue acts in the same manner
as its corresponding methylphenidate counterpart at hDAT. As with
its methylphenidate counterpart, the naphthyl compound also acts,
rather uniquely (although with lower potency) relative to other members
of the two series, at the human serotonin transporter (hSERT). In
conclusion, the benzoylpiperidines represent a novel structural class
of hDAT reuptake inhibitors that function in a manner similar to their
methylphenidate counterparts.